1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Monoclonal Antibodies Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Monoclonal Antibodies Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Monoclonal Antibodies Market Regional Analysis
6.2 Europe Monoclonal Antibodies Market Revenue 2019-2028 (US$ Million)
6.3 Europe Monoclonal Antibodies Market Forecast Analysis
7. Europe Monoclonal Antibodies Market Analysis – by Source
7.1 Human
- 7.1.1 Overview
- 7.1.2 Human: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Humanized
- 7.2.1 Overview
- 7.2.2 Humanized: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Chimeric
- 7.3.1 Overview
- 7.3.2 Chimeric: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Murine
- 7.4.1 Overview
- 7.4.2 Murine: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Europe Monoclonal Antibodies Market Analysis – by Production Method
8.1 In-Vitro
- 8.1.1 Overview
- 8.1.2 In-Vitro: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 In-Vivo
- 8.2.1 Overview
- 8.2.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Europe Monoclonal Antibodies Market Analysis – by Indication
9.1 Cancer
- 9.1.1 Overview
- 9.1.2 Cancer: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Autoimmune Diseases
- 9.2.1 Overview
- 9.2.2 Autoimmune Diseases: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 Infectious Diseases
- 9.3.1 Overview
- 9.3.2 Infectious Diseases: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.4 Inflammatory Diseases
- 9.4.1 Overview
- 9.4.2 Inflammatory Diseases: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.5 Microbial Diseases
- 9.5.1 Overview
- 9.5.2 Microbial Diseases: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. Europe Monoclonal Antibodies Market Analysis – by Application
10.1 Therapeutic Applications
- 10.1.1 Overview
- 10.1.2 Therapeutic Applications: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Diagnostic Applications
- 10.2.1 Overview
- 10.2.2 Diagnostic Applications: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.3 Research Applications
- 10.3.1 Overview
- 10.3.2 Research Applications: Europe Monoclonal Antibodies Market – Revenue and Forecast, 2019-2028 (US$ Million)
11. Europe Monoclonal Antibodies Market – Europe Analysis
11.1 Overview
11.2 Europe
- 11.2.1 Europe Monoclonal Antibodies Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 11.2.1.1 Europe Monoclonal Antibodies Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 UK:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 UK: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.1.2 UK: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.1.3 UK: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.1.4 UK: Europe Monoclonal Antibodies Market Breakdown, by Application
- 11.2.1.2 Germany:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Germany: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.2.2 Germany: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.2.3 Germany: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.2.4 Germany: Europe Monoclonal Antibodies Market Breakdown, by Application
- 11.2.1.3 France:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 France: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.3.2 France: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.3.3 France: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.3.4 France: Europe Monoclonal Antibodies Market Breakdown, by Application
- 11.2.1.4 Russia:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.4.1 Russia: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.4.2 Russia: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.4.3 Russia: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.4.4 Russia: Europe Monoclonal Antibodies Market Breakdown, by Application
- 11.2.1.5 Italy:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.5.1 Italy: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.5.2 Italy: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.5.3 Italy: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.5.4 Italy: Europe Monoclonal Antibodies Market Breakdown, by Application
- 11.2.1.6 Rest of Europe:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.6.1 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Source
- 11.2.1.6.2 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 11.2.1.6.3 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 11.2.1.6.4 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Application
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Novartis AG
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Amgen Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 DAIICHI SANKYO COMPANY, LIMITED
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 F. Hoffmann-La Roche Ltd.
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AstraZeneca
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Eli Lilly and Company
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Bayer AG
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Bristol-Myers Squibb Company
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Get Free Sample For Europe Monoclonal Antibodies Market
